drugset / Trial / NCT07454187
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2026-04-16
- Primary completion
- 2027-09-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SG2918 | Unknown | 1.5 mg/kg | Intravenous |
| Subject | SG2918 | Unknown | 1.8 mg/kg | Intravenous |
| Subject | SG2918 | Unknown | 2 mg/kg | Intravenous |